INVESTOR CONTACT:Michael SchaffzinStern Investor Relations, Inc.212-362-1200 email@example.comMEDIA CONTACT: Annie Starr6 Degrees973-415-8838 firstname.lastname@example.org
STAMFORD, Conn., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will participate in a fireside chat at the 28 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016, at 4:30 p.m. ET in New York City. A live webcast of the presentation can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days. About Cara Therapeutics Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.